Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Olema Pharmaceuticals (OLMA) Operating Income (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Operating Income data on record, last reported at -$58.0 million in Q1 2026.

  • On a quarterly basis, Operating Income fell 66.28% to -$58.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$201.8 million, a 41.33% decrease, with the full-year FY2025 number at -$178.7 million, down 25.62% from a year prior.
  • Operating Income reached -$58.0 million in Q1 2026 per OLMA's latest filing, down from -$50.1 million in the prior quarter.
  • Over the last five years, Operating Income for OLMA hit a ceiling of -$21.6 million in Q2 2023 and a floor of -$58.0 million in Q1 2026.
  • A 5-year average of -$34.8 million and a median of -$33.5 million in 2024 define the central range for Operating Income.
  • Peak YoY movement for Operating Income: plummeted 101.51% in 2022, then soared 35.12% in 2023.
  • Tracing OLMA's Operating Income over 5 years: stood at -$27.2 million in 2022, then decreased by 11.75% to -$30.4 million in 2023, then fell by 20.88% to -$36.8 million in 2024, then crashed by 36.22% to -$50.1 million in 2025, then dropped by 15.78% to -$58.0 million in 2026.
  • Business Quant data shows Operating Income for OLMA at -$58.0 million in Q1 2026, -$50.1 million in Q4 2025, and -$45.9 million in Q3 2025.